文献速递妇科肿瘤

JQ1联合顺铂抑制卵巢癌生长并抑制JAK/STAT信号通路

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
PubMed 文献 · Eur J Cancer · 2020-01-09

该研究在卵巢癌细胞系及人卵巢癌腹水原代细胞中评估JQ1的作用,发现JQ1通过靶向BRD4和c-Myc抑制增殖并诱导凋亡,且可增敏顺铂,包括对单用顺铂耐药的卵巢细胞;JQ1还作用于JAK-STAT通路。结论提示JQ1是卵巢癌尤其是铂耐药或复发患者的潜在抗肿瘤候选药物。

要点

  • JQ1靶向BRD4和c-Myc抑制卵巢癌细胞增殖并诱导凋亡
  • JQ1可增敏顺铂,且在单用顺铂耐药的卵巢细胞中仍观察到该效应
  • JQ1作用于支持卵巢癌细胞存活的JAK-STAT信号通路

核心结论

  • JQ1是值得进一步研究的卵巢癌抗肿瘤候选药物,尤其可能适用于铂耐药或复发患者。

研究设计与样本

  • 研究使用一组卵巢癌细胞系及来自人卵巢癌腹水的原代细胞培养进行体外实验。

主要发现

  • JQ1通过靶向BRD4和c-Myc显著抑制卵巢癌细胞增殖并诱导凋亡。
  • JQ1使卵巢癌细胞对顺铂增敏,且在单用顺铂耐药的卵巢细胞中仍观察到该效应。
  • JQ1与JAK-STAT信号通路相互作用,抑制或诱导分别参与细胞存活和凋亡的基因。

临床怎么用

  • 结果提示JQ1联合顺铂可能作为卵巢癌尤其是铂耐药或复发患者的候选治疗策略,尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective small-molecule BET (Bromodomain and extraterminal domain family) bromodomain (BRDs) inhibitor, has been found to suppress tumour progression in several cancer cell types. RESULTS: Using a panel of ovarian cancer cell lines and primary cell cultures from human ovarian cancer ascites, we demonstrated that JQ1 significantly suppressed cell proliferation and induced apoptosis in an ovarian cancer cell by targeting BRD4 and c-Μyc. In addition, JQ1 sensitized ovarian cancer cells to cisplatin, the most commonly used chemotherapeutic agent in ovarian cancer. Importantly, this effect was observed in ovarian cells, which exhibited resistance to cisplatin alone. Finally, we show that JQ1 interacts with the JAK-STAT signalling pathway, a pathway important in supporting ovarian cancer cell survival by suppressing or inducing genes involved in cell survival and apoptosis, respectively. CONCLUSION: Our data, taken together, suggest that JQ1 is an attractive antitumour candidate for further investigation in the treatment of ovarian cancer, as it associates with cell proliferation, apoptosis, and alterations in the JAK-STAT signalling pathway, especially in patients with a platinum-resistant profile or in patients with relapsed disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bagratuni T, Mavrianou N, Gavalas NG, et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. Eur J Cancer. 2020. PMID: 31927213. doi:10.1016/j.ejca.2019.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。